The $100,000 problem gene therapy companies would rather not mention
The high doses of recently studied gene therapies threaten manufacturing problems that few have fully considered.
Reasons to be cautious about new haemophilia therapies
Roche's Hemlibra has impressed, but uptake might not be as fast as some hope.
Canada’s medical cannabis ambition no laughing matter
Growing acceptance of medical marijuana could see cannabis companies coming after pharma sales.
Preventive Alzheimer’s trials keep amyloid hope alive
Drugs have so far failed to make an impact in established Alzheimer's disease, so research is moving towards efforts to prevent the disorder.
Vertex and orphan drugs test limits of US payers
Vertex's cystic fibrosis drugs are among the most expensive ever evaluated by the US Institute for Clinical and Economic Research.
Solving the incremental innovation dilemma
Could pricing pressure lead to the end of incremental innovation – and why does this matter?
As US hospitals consolidate their pharmacy muscles grow
Consolidation of hospital chains could give biopharma another powerful group of payers to contend with.
Biotech gets creative about the pay cheque
Amid a backlash over the high prices of advanced therapies, biotech companies are coming up with new payment models.
European approvals face delay from agency move
How the EMA's move out of London could impact European drug approvals.